NT_1170x120_1-11-18

Red Oak Sourcing

Cardinal has tools to make health care work better

Cardinal has tools to make health care work better

DUBLIN, Ohio — Cardinal Health is prepared to play a significant role in meeting the challenge of expanding access, improving patient outcomes and lowering costs in health care, said chairman and chief executive officer George Barrett. With its integrated offerings, Cardinal Health is an essential partner for pharmacies, physicians’ offices, hospitals and other providers in

CVS well positioned to create value in health care

CVS well positioned to create value in health care

NEW YORK — CVS Health has raised the midpoint of its earnings outlook for 2016 and reiterated its five-year steady state targets. The company now expects next year’s adjusted earnings per share to range from $5.73 to $5.88, reflecting solid year-over-year growth of 11.25% to 14.25%. The bottom end of the range was increased by

CVS Health’s Merlo: ‘No one is better positioned’

CVS Health’s Merlo: ‘No one is better positioned’

NEW YORK — At its annual Analyst Day event here, CVS Health updated its earnings guidance for 2016 and reiterated its five-year targets. “Over the past several years, CVS Health has been preparing for the changes in the health care landscape by expanding our extensive suite of leading assets and capabilities,” said president and chief

Harvard Drug Group sold to Cardinal

DUBLIN, Ohio — Cardinal Health Inc. plans to acquire pharmaceutical distributor The Harvard Drug Group (THDG) from private equity firm Court Square Capital Partners for $1.12 billion. Based in Livonia, Mich., THDG is a distributor of generic drugs, over-the-counter medicines and related products to retail, institutional and alternate care customers. THDG had revenue of about

Generics drugs loom larger than ever in health care

Generics drugs loom larger than ever in health care

NEW YORK — As the nation becomes more focused on affordable health care, generic drug companies are carving out a larger share of the U.S. market for prescription drugs. Perhaps the most significant sign of this continuing shift to generic drug utilization shows up in the market share data for actual prescriptions dispensed, brands compared